SQZ Biotechnologies Co is a clinical-stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions... Show more
SQZB saw its Momentum Indicator move above the 0 level on November 13, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned positive. In of the 93 cases, the stock moved higher in the following days. The odds of a move higher are at .
The Moving Average Convergence Divergence (MACD) for SQZB just turned positive on November 07, 2025. Looking at past instances where SQZB's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 40 cases where SQZB's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
SQZB moved below its 50-day moving average on October 20, 2025 date and that indicates a change from an upward trend to a downward trend.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.376) is normal, around the industry mean (23.122). P/E Ratio (0.000) is within average values for comparable stocks, (61.014). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.073). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (0.058) is also within normal values, averaging (332.704).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. SQZB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SQZB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Industry Biotechnology
A.I.dvisor indicates that over the last year, SQZB has been loosely correlated with MDGL. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if SQZB jumps, then MDGL could also see price increases.
| Ticker / NAME | Correlation To SQZB | 1D Price Change % | ||
|---|---|---|---|---|
| SQZB | 100% | N/A | ||
| MDGL - SQZB | 33% Loosely correlated | +1.01% | ||
| ARRY - SQZB | 33% Loosely correlated | -3.82% | ||
| AXON - SQZB | 33% Poorly correlated | -1.74% | ||
| MIST - SQZB | 31% Poorly correlated | +3.88% | ||
| LYRA - SQZB | 29% Poorly correlated | -2.41% | ||
More | ||||